JP2005538065A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538065A5
JP2005538065A5 JP2004513473A JP2004513473A JP2005538065A5 JP 2005538065 A5 JP2005538065 A5 JP 2005538065A5 JP 2004513473 A JP2004513473 A JP 2004513473A JP 2004513473 A JP2004513473 A JP 2004513473A JP 2005538065 A5 JP2005538065 A5 JP 2005538065A5
Authority
JP
Japan
Prior art keywords
serotonin
antagonist
compound
fluphenazine
brain barrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004513473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/019595 external-priority patent/WO2003106660A2/en
Publication of JP2005538065A publication Critical patent/JP2005538065A/ja
Publication of JP2005538065A5 publication Critical patent/JP2005538065A5/ja
Pending legal-status Critical Current

Links

JP2004513473A 2002-06-17 2003-06-17 セロトニンファミリーの受容体および血液脳関門に関する免疫調節および細胞過程への影響 Pending JP2005538065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38957702P 2002-06-17 2002-06-17
US41483102P 2002-09-27 2002-09-27
PCT/US2003/019595 WO2003106660A2 (en) 2002-06-17 2003-06-17 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier

Publications (2)

Publication Number Publication Date
JP2005538065A JP2005538065A (ja) 2005-12-15
JP2005538065A5 true JP2005538065A5 (https=) 2006-07-27

Family

ID=29740159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004513473A Pending JP2005538065A (ja) 2002-06-17 2003-06-17 セロトニンファミリーの受容体および血液脳関門に関する免疫調節および細胞過程への影響

Country Status (7)

Country Link
US (2) US20060183757A1 (https=)
EP (1) EP1534256A4 (https=)
JP (1) JP2005538065A (https=)
CN (2) CN1674879A (https=)
AU (1) AU2003276445A1 (https=)
CA (1) CA2488708A1 (https=)
WO (1) WO2003106660A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003996A1 (en) * 2002-06-17 2006-01-05 Stephen Roth Intralesional treatment of psoriasis
KR100675432B1 (ko) * 2004-10-04 2007-01-29 캄텍주식회사 차량 배기 가스 재순환 밸브의 개폐 구조
US20060287301A1 (en) * 2005-06-17 2006-12-21 Mcnair Douglas Novel formulations for phenothiazines, including fluphenazine and its derivatives
EP2061788A4 (en) * 2006-09-01 2010-10-06 Immune Control Inc NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED LYMPHOCYTES
JP2008156297A (ja) * 2006-12-25 2008-07-10 Hokkaido Univ セロトニン２ｂおよび／または２ｃ受容体拮抗剤
GB0701170D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
EP2420238A3 (en) 2007-04-13 2012-03-07 Southern Research Institute Anti-angiogenic agents
JP2011513319A (ja) * 2008-02-29 2011-04-28 イミューン コントロール インコーポレイテッド 活性化リンパ球に関連する疾患の処置のための組成物
CN101970427A (zh) 2008-02-29 2011-02-09 Vm生物医药公司 治疗疼痛症状及其它失调的方法
JP2011516486A (ja) * 2008-03-31 2011-05-26 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 骨質量疾患の診断、予防、及び治療方法
WO2010124100A1 (en) * 2009-04-22 2010-10-28 Immune Control, Inc. Novel selective 5-ht4 receptor antagonists
WO2011053977A1 (en) 2009-11-02 2011-05-05 The Trustees Of Columbia University In The City Of New York Compounds and methods for inhibiting serotonin synthesis
US20130287705A1 (en) * 2010-11-03 2013-10-31 Mcmaster University Method of treating mucosal inflammation
TR201903280T4 (tr) * 2011-08-02 2019-04-22 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Malt1 proteazının fenotiazin türevleri ile selektif inhibisyonu.
WO2019175332A1 (en) * 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
AU2023298975A1 (en) * 2022-06-30 2025-02-13 Gexval Inc. Pharmaceutical composition
CN116731165B (zh) * 2023-03-23 2024-08-13 北京巴瑞医疗器械有限公司 一种抗血清素抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
EP0489108B1 (en) * 1989-08-21 1996-03-13 Beth Israel Hospital Association Use of spiperone derivatives for immunosuppression
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
WO1992016226A1 (en) * 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
US5658955A (en) * 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
WO2002057244A1 (en) * 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
WO2002078643A2 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen

Similar Documents

Publication Publication Date Title
JP2005538065A5 (https=)
Watad et al. The early phases of ankylosing spondylitis: emerging insights from clinical and basic science
Salazar et al. Alzheimer's disease risk factor Pyk2 mediates amyloid-β-induced synaptic dysfunction and loss
Tillage et al. Elimination of galanin synthesis in noradrenergic neurons reduces galanin in select brain areas and promotes active coping behaviors
Gallagher et al. Relationship of age-related decline across several behavioral domains
Pelleymounter et al. Hippocampal 3H-CPP binding and spatial learning deficits in aged rats
Yang et al. Increased asynchronous release and aberrant calcium channel activation in amyloid precursor protein deficient neuromuscular synapses
Yoneda et al. Peripubertal exposure to the neonicotinoid pesticide dinotefuran affects dopaminergic neurons and causes hyperactivity in male mice
Le et al. Prion neurotoxicity
Dahdah et al. Germinal center B cells are essential for collagen‐induced arthritis
Gherzi et al. Reevaluation of the evidence that an antibody to the insulin receptor is insulinmimetic without activating the protein tyrosine kinase activity of the receptor.
DE3650647T2 (de) Arzneimittel zur Behandlung von Anxietas
Rana et al. Constitutive vagus nerve activation modulates immune suppression in sepsis survivors
Chang et al. Brazilin isolated from Caesalpinia sappan L. acts as a novel collagen receptor agonist in human platelets
JP2014210824A (ja) 胃腸疾患の治療方法および組成物
Ghidoni et al. Circulating progranulin as a biomarker for neurodegenerative diseases
Peng et al. MAdCAM-1 mediates retinal neuron degeneration in experimental colitis through recruiting gut-homing CD4+ T cells
Karnabi et al. Rescue and worsening of congenital heart block‐associated electrocardiographic abnormalities in two transgenic mice
Rosendahl et al. Adaptive immunity and IL‐17A are not involved in the progression of chronic kidney disease after 5/6 nephrectomy in mice
Van der Zee et al. Delayed peripheral nerve regeneration and central nervous system collateral sprouting in leucocyte common antigen‐related protein tyrosine phosphatase‐deficient mice
Erdogan et al. Neuronal–immune axis alters pain and sensory afferent damage during dental pulp injury
Lauten et al. TH17/Treg lymphocyte balance is regulated by beta adrenergic and cAMP signaling
ES2331451B1 (es) Inmunosupresor basado en la interrupcion de la interaccion tcr-nck.
Friedman et al. Cleft palate, retrognathia and congenital heart disease in velo-cardio-facial syndrome: a phenotype correlation study
Schmidt Memory loss by glutamate antagonists: an animal model of Alzheimer’s disease?